Showing results (91-100 of 164) with videos related to

Sort By:
Pageof 17
Leukemia Research|July 31, 2018
A seven-color panel including CD34 and TdT could be applied in >97% patients with T cell lymphoblastic leukemia for minimal residual disease detection independent of the initial phenotypeYa-Zhe Wang, Le Hao, Yan Chang, et al.
Leukemia & Lymphoma|September 9, 2020
High PRDM16 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk: a comprehensive cohort study from a single Chinese centerFeng-Ting Dao, Wen-Min Chen, Ling-Yu Long, et al.
Acta Haematologica|November 29, 2008
Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variantYa Zhen Qin, Bin Jiang, Qian Jiang, et al.
Hematological Oncology|May 9, 2022
Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remissionJun Wang, Feng-Ting Dao, Yu Wang, et al.
International Journal of Laboratory Hematology|July 15, 2025
The Characteristics and Outcomes of Adult Acute Myeloid Leukemia Patients With KMT2A-Partial Tandem DuplicationDai-Hong Xie, Wen-Min Chen, Yue Hao, et al.
DNA and Cell Biology|September 28, 2017
PRAME Gene Copy Number Variation Is Related to Its Expression in Multiple MyelomaLu Yang, Ya-Zhe Wang, Hong-Hu Zhu, et al.
Frontiers in Immunology|July 25, 2022
Low IL7R Expression at Diagnosis Predicted Relapse in Adult Acute Myeloid Leukemia Patients With t(8;21)Nan Xu, Kai Sun, Ya-Zhe Wang, et al.
Leukemia Research|July 2, 2013
Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?Ya-Zhen Qin, Qian Jiang, Hao Jiang, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi|April 22, 2009
[Relationship of immunophenotypic features with minimal residual disease detection and gene types in 221 cases of acute promyelocytic leukemia]Ya-Zhe Wang, Ya-Zhen Qin, Bin Jiang, et al.
Hematological Oncology|March 10, 2024
Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemiaYuan Sun, Xu Wang, Wen-Min Chen, et al.
Pageof 17